An update from SSY Group ( (HK:2005) ) is now available.
SSY Group Limited has announced the approval of its SYN045 tablets for Phase I clinical trials by the National Medical Products Administration of China. The approval includes three different specifications, which will enhance the clinical application and dosing precision of the drug. SYN045, a PGI2 receptor agonist, has shown promising results in preclinical studies with good targeting selectivity and safety, marking a significant step forward in the company’s drug development efforts.
More about SSY Group
SSY Group Limited is a company operating in the pharmaceutical industry, focusing on the development of chemical drugs. The company is involved in creating innovative medications, with a particular emphasis on targeting specific health conditions such as pulmonary hypertension.
YTD Price Performance: 2.09%
Technical Sentiment Signal: Buy
Current Market Cap: $1.28B
For a thorough assessment of 2005 stock, go to TipRanks’ Stock Analysis page.